Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up

MLA

Mattia Parisi, et al. “Efficacy of Rituximab in Anti‐myelin‐associated Glycoprotein Demyelinating Polyneuropathy: Clinical, Hematological and Neurophysiological Correlations during 2 Years of Follow‐up.” European Journal of Neurology, vol. 29, Sept. 2022, pp. 3611–22. EBSCOhost, https://doi.org/10.1111/ene.15553.

APA

Mattia Parisi, Irene Dogliotti, Michele Clerico, Davide Bertuzzo, Giulia Benevolo, Lorella Orsucci, Irene Schiavetti, Roberto Cavallo, Federica Cavallo, Simone Ragaini, Alessandra Di Liberto, Martina Ferrante, Giulia Bondielli, Carlo Alberto Artusi, Daniela Drandi, Leonardo Lopiano, Bruno Ferrero, & Simone Ferrero. (2022). Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up. European Journal of Neurology, 29, 3611–3622. https://doi.org/10.1111/ene.15553

Chicago

Mattia Parisi, Irene Dogliotti, Michele Clerico, Davide Bertuzzo, Giulia Benevolo, Lorella Orsucci, Irene Schiavetti, et al. 2022. “Efficacy of Rituximab in Anti‐myelin‐associated Glycoprotein Demyelinating Polyneuropathy: Clinical, Hematological and Neurophysiological Correlations during 2 Years of Follow‐up.” European Journal of Neurology 29 (September): 3611–22. doi:10.1111/ene.15553.